Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB071 and BYL719 in Metastatic Uveal Melanoma
NCT02273219Phase 1Completed
- Sponsor
- Columbia University
- Start
- Nov 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotrastaurin and alpelisib in Uveal melanoma (UM) (5 arms), sponsored by Columbia University. Primary endpoint: Maximum Tolerated Dose at 4 years. Started Nov 2014; status: completed.
02
Drugs
sotrastaurinalpelisib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02273219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273219.